Janux Therapeutics Inc Stock News

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event.

Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA reduction and favorable safety profile in phase 1 trials for metastatic castration-resistant prostate cancer. JANX007's innovative design addresses limitations of previous T cell engagers, showing ...

SAN DIEGO--(BUSINESS WIRE)---- $JANX--3Q24 Earnings Release.

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights.

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to ...

Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies to fight cancer, with promising drug candidates targeting PSMA and EGFR. JANX's TRACTr and TRACIr platforms engineer drug candidates that activate T cells in the tumor microenvironment, showing promising results in clinical trials. JANX007 achieved a 50% PSA reduction in 83% of mCRPC patients at 0.2mg or higher. ...